Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1

Theranexus, a company specializing in the treatment of rare neurological diseases, revealed its cash flow as of June 30, 2024, standing at 1.8 million euros, compared to 3.1 million euros as of March 31, 2024. Research Tax Credit 2023 has not yet been seen.

At the same time, Theranexus and the BBDF Foundation validated the criteria for evaluating the effectiveness of Batten-1 with the FDA and the EMA. The company is focusing on the visual acuity endpoint in a population of young patients for phase 3 of the study.

In order to finance this study, Theranexus is setting up a new equity financing line of 2.5 million euros over 24 months through the issue of bonds subscribed by IRIS. The details and conditions of this operation are specified in the press release.